On September 29, 2026, Erick Frim notified Apimeds Pharmaceuticals US, Inc., a Delaware corporation (the “Company”), of his resignation as Interim Chief Financial Officer of the Company, effective immediately. As previously disclosed, Mr...
To the extent required by Item 3.03 of Form 8-K, the information regarding the Reverse Stock Split and Charter Amendment set forth in Item 5.03 of this Current Report on Form 8-K is incorporated by reference herein.
This First Amendment to Confidential Settlement and Mutual Release Agreement (this “Amendment”) between Apimeds Pharmaceuticals US, Inc., a Delaware corporation (“Company”), MindWave Innovations Inc, a Delaware corporation and a wholly o...